Scleroderma overlap syndromes.

Area of Science:

• Rheumatology
• Immunology
• Genetics

Background:

• Scleroderma overlap syndromes are common, with mixed connective tissue disease (MCTD), scleromyositis, and synthetase syndrome being most frequent.
• MCTD's classification is debated due to heterogeneous manifestations and potential evolution into defined connective tissue diseases (CTDs).

Purpose of the Study:

• To investigate the clinical characteristics and evolution of scleroderma overlap syndromes.
• To analyze the immunogenetic associations and distinct features of scleromyositis and synthetase syndrome.

Main Methods:

• Retrospective study of 114 patients (94 adults, 20 children) classified using Alarcon-Segovia criteria with 5-9 year follow-up.
• Analysis of antibody profiles (U1 RNP, PM-Scl, anti-histidyl-tRNA synthetase) and immunogenetic associations (HLA alleles).
• Comparison of clinical features and treatment responses across different overlap syndromes.

Main Results:

• Over 20% of MCTD patients transformed into SLE or SSc; over half remained undifferentiated CTD.
• Scleromyositis (83% of PM-Scl positive cases) showed dermatomyositis features without SLE, associated with HLA-DQA1*0501 and HLA-DRB1*0301.
• Synthetase syndrome cases with ILD rarely had scleroderma features, presenting acutely with fever and responding to corticosteroids.

Conclusions:

• Scleroderma overlap syndromes are heterogeneous, with MCTD exhibiting significant transformation rates.
• Scleromyositis and synthetase syndrome represent distinct overlap entities with unique clinical, serological, and immunogenetic profiles.
• Understanding these distinctions is crucial for accurate diagnosis and management of patients with overlapping autoimmune rheumatic diseases.